

OIPE OIPE OF THE PROPERTY OF T

Docket No. J&J1886CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Miri Seiberg et al.

Serial No. : 10/689,149

Art Unit: 1616

Filed

: October 20, 2003

Examiner:

For

: Topical Anti-Cancer Compositions and Methods of

Use Thereof

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

July 9, 2004 (Hate of Deposit)

Andrea L. Colby (Name of applicant, assignee, or Registered Representative)

(Signature)

(pate of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on March 15, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information \boxtimes Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of

either a Final Action under §1.113 or a Notice of Allowance

under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p). \Box Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. Identification of Prior Application in Which Listed \boxtimes Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted. \boxtimes This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application SN.: 09/698,454, filed on 10/27/2000. The following references were submitted to, \boxtimes and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application: All. \boxtimes If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). \Box There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

English language claims are provided for EP 0643083 Al from its Bl document, a copy of which is also provided.

English language abstracts are provided for CN 1094279, FR 2596986, FR 2641696, FR 2685202, JP 6145061, JP 6192085, JP 7010772, JP 7196527, JP 7196529, JP 8040824, JP 8059450, JP 8143442, JP 8333260, JP 9059166, JP 9077638, JP 9176033, JP 58225004, JP 59187756, JP 2000302678, KR 92-8853, and WO 97/11033.

English language translations are provided for EP 0421021, FR 2803747, FR 2811226, JP 1096106, JP 3127713, JP 4169514, JP 5015574, JP 5213729, JP 5246932, JP 5320024, JP 5320061, JP 7304655, JP 8012560, JP 8020597, JP 8099891, JP 9025212, JP 9025214, JP 11346695, JP 58225003, JP 62036304, JP 63068512, JP 63096120, JP 63227515, JP 63316711, KR 92-8851, RU 2066992, WO 96/40121, WO 99/09065, WO 00/15188, WO 02/07697, HAMADA J. Soc. Cosmet. Chem. Japan 31(4):413-419 1997, and WANG Acta Entomologica Sinica 38(3):272-274 1995.

English language equivalents are provided as follows:

EP 0643960 - US 5,741,496

EP 0655470 - US 5,712,356 & 5,936,052

EP 0661037 - US 5,629,015

EP 0814116 - US 5,871,823

JP 5114905 - EP 0508886

WO 87/07838 - US 4,978,528

WO 98/33089 - US 6,018,001

WO 02/07697 - US 2004/009142

Attached are copies of patent applications/patents which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/J&J1886CIP1/ALC. This form is submitted in triplicate.

Respectfully submitted,

Andrea L. Co

Reg. No. 30,194

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003

(732) 524-2792

DATED: July 9, 2004

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sugstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

U.S. PATENT DOCUMENTS

		U.S. Patent Document	<u> </u>	U.S. PATENT DOCUMENTS		
Examiner Cite No.1 Number			d Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		3,097,947	Α	Kemmerer	07-16-1963	
		3,625,976	Α	Theimer	12-07-1971	
		3,755,560	Α	Dickert	08-28-1973	
		4,007,266	Α	Choay	02-08-1977	
-		4,056,637	Α	Hagiwara et al	11-01-1977	
		4,151,304	Α	Evans	04-24-1979	
		4,190,671	Α	Vanstone	02-26-1980	
		4,219,569	Α	Glenn	08-26-1980	
		4,223,018	Α	Belle	09-16-1980	
		4,254,105	Α	Fukuda	03-03-1981	
		4,272,544	Α	Cella	06-09-1981	
		4,278,570	Α	Flom	07-14-1981	
		4,279,930	A	Hall	09-14-1979	
		4,297,348	Α	Frazier	10-27-1981	
		4,331,692	Α	Drevici	05-25-1982	
		4,333,927	Α	Ofuchi	06-08-1982	
		4,368,187	Α	Flom	01-11-1983	
		4,370,315	Α	Greff	01-25-1983	
		4,382,960	Α	Flom	05-10-1983	
		4,386,067	Α	Guillon	05-31-1983	
		4,421,769	Α	Dixon	12-20-1983	
		4,427,670	Α	Ofuchi	01-24-1984	
		4,434,095	Α	Chipens et al.	02-28-1984	
		4,437,895	Α	Koulbanis	03-20-1984	
		4,439,418	Α	Moller	03-27-1984	
		4,462,981	Α	Smith	07-21-1984	
~		4,477,434	Α	Kosaka	10-16-1984	

Examiner	Date	1	
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

U.S. PATENT DOCUMENTS

		U.S. Patent Document		D-4(D-1-11	D C-l li	
Examiner Initials	Cite No. ¹	ا ا	1 1	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		4,486,448	Α	Ser	12-04-1984	·
		4,488,564	Α	Grollier	12-18-1984	
		4,515,778	Α	Kastell	05-07-1985	
		4,524,067	Α	Arichi	06-18-1985	
		4,537,782	Α	Millet	08-27-1985	
		4,550,035	Α	Smith	10-29-1985	
		4,578,267	Α	Salamone	03-25-1986	
		4,584,190	Α	Tejima	04-22-1986	
		4,604,281	Α	Deckner	08-05-1986	
		4,612,192	Α	Scheuffgen	09-16-1986	
		4,690,821	Α	Smith	09-01-1987	
		4,707,293	Α	Ferro	12-17-1987	
		4,760,096	Α	Sakai	07-26-1988	
		4,793,991	Α	Slimak	12-27-1988	
		4,824,662	Α	Hofmann	04-25-1989	•
		4,834,076	Α	Millet	05-30-1989	
		4,847,267	Α	Deckner	07-11-1989	
		4,851,214	Α	Walters	07-25-1989	
		4,859,458	Α	Salamone	08-22-1989	
		4,867,964	Α	Forestier	09-19-1989	
		4,871,530	Α	Grollier	10-03-1989	
		4,885,169	Α	Gazzani	12-05-1989	
		4,895,839	Α	Bombardelli	01-23-1990	
		4,906,457	Α	Ryan	03-06-1990	
		4,943,462	Α	Komerska	07-24-1990	
		4,960,588	Α	Hoshowski	10-02-1990	
		4,960,764	Α	Figueroa	10-02-1990	· · · · · · · · · · · · · · · · · · ·

_		
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

U.S. PATENT DOCUMENTS

		U.S. Patent Document		U.S. PATENT DOCUMENTS		
Examiner			d Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
Initials 1	No. ¹	Number (if	known)	or Cited Document	mm-dd-yyyy	or relevant figures appear
		4,970,216	Α	Deckner	11-13-1990	
		4,971,825	Α	Kitazume et al.	11-20-1990	
		4,978,528	Α	Degre	12-18-1990	
		5,002,761	Α	Mueller	03-26-1991	
		5,032,382	Α	Crollie	07-16-1991	
		5,032,400	Α	Wiersum	07-16-1991	
		5,043,323	Α	Bombardelli	08-27-1991	
		5,057,417	Α	Hammonds et al.	10-15-1991	
		5,077,038	A	Hofmann	12-31-1991	
		5,077,040	A	Bergmann	12-31-1991	
		5,104,655	Α	Bombardelli	04-14-1992	
		5,110,603	A	Rau	05-05-1992	
		5,116,605	Α	Alt	05-26-1992	
		5,118,671	Α	Bombardelli	06-02-1992	
		5,130,142	Α	Wong et al.	07-14-1992	
		5,147,859	Α	Bombardelli	09-15-1992	
		5,166,139	Α	Bombardelli	11-24-1992	
		5,171,577	Α	Griat	12-15-1992	
		5,179,091	Α	Lesieur	01-12-1993	
		5,188,823	Α	Shapiro	02-23-1993	
		5,192,332	Α	Lang	03-09-1993	
		5,194,252	Α	Hofmann	03-16-1993	
		5,217,717	Α	Kennedy	06-08-1993	
		5,229,104	Α	Sottery	07-20-1993	
		5,231,090	Α	Hsia	07-27-1993	
		5,248,495	Α	Patterson	09-28-1993	
		5,254,331	Α	Mausner	10-19-1993	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 4 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

U.S. PATENT DOCUMENTS

	T = = -	U.S. Patent Document		U.S. PATENT DOCUMENTS	1	
Examiner	ner Cite	te Kind Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages	
Initials N	No.1	Number	(if known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
		5,260,065	Α	Mathur	11-09-1993	
		5,270,042	Α	Whitham	12-14-1993	
		5,276,058	Α	Satoh	01-04-1994	
		5,306,444	Α	Kitamura	04-26-1994	
		5,310,734	Α	Losch	05-10-1994	
		5,322,839	A	Voegeli	06-21-1994	
		5,352,443	A	Kubo	10-04-1994	
		5,362,494	Α	Zysman	11-08-1994	
		5,364,886	Α	Loliger	11-15-1994	
		5,393,519	A	Dowell	02-28-1995	
		5,397,497	Α	Jakobson	03-14-1995	
		5,407,675	Α	Etemad-Moghadam	04-18-1995	
		5,411,742	Α	Sebag	05-02-1995	
		5,427,814	Α	Loliger	06-27-1995	
		5,428,026	Α	Colarow	06-27-1995	
		5,438,044	Α	Losch	08-01-1995	
		5,439,672	Α	Zabotto	08-08-1995	
		5,443,839	Α	Meybeck	08-22-1995	
,		5,443,840	Α	Morancais	08-22-1995	
		5,446,605	Α	Umehara	08-29-1995	
		5,466,452	Α	Whittle	11-14-1995	
		5,498,420	Α	Mentrup Edgar	03-12-1996	
		5,503,832	Α	De Stoutz	04-02-1996	
		5,505,946	Α	Kennedy et al.	04-09-1996	
		5,510,391	Α	Elson	04-23-1996	
		5,523,308	Α	Costanzo	06-04-1996	
		5,539,129	Α	Zysman	07-23-1996	

Examiner		Date		
Signature		Conside	ered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 5 of 22

10/689,149
10-20-2003
Miri Seiberg et al.
1616
J&J1886CIP1
i

U.S. PATENT DOCUMENTS

	 	U.S. Patent Document		U.S. PATENT DOCUMENTS		
Examiner	Cite		d Code ²	Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
Initials	No.1	ł	known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		5,545,399	Α	Lee	08-13-1996	
		5,547,661	Α	Sun	08-20-1996	
		5,554,647	Α	Perricone	09-10-1996	
		5,565,439	Α	Piazza et al.	10-15-1996	-
		5,565,493	Α	Nakata et al.	10-15-1996	
		5,567,420	Α	McEleney	10-22-1996	
		5,569,663	Α	Ribier	10-29-1996	
		5,571,503	A	Mausner	11-05-1996	
		5,578,297	Α	Mellul	11-26-1996	
		5,589,181	A	Bencsits	12-31-1996	
		5,595,984	A	Blank	01-21-1997	
		5,597,814	A	Blank	01-28-1997	
		5,601,833	Α	Roboer	02-11-1997	
		5,603,949	Α	Meybeck	02-18-1997	
		5,605,894	Α	Blank	02-25-1997	
		5,607,666	Α	Masson	03-04-1997	
		5,607,692	Α	Ribier	03-04-1997	
		5,614,180	Α	Chung	03-25-1997	
		5,614,215	Α	Ribier	03-25-1997	
		5,616,572	Α	Blank	. 04-01-1997	
		5,618,522	Α	Kaleta	04-08-1997	
		5,620,692	Α	Potter	04-15-1997	
		5,622,690	Α	Potter	04-22-1997	
		5,626,868	Α	Morancais	05-06-1997	
		5,629,015	Α	Ribier	05-13-1997	
		5,629,301	Α	Blank	05-13-1997	
		5,631,318	Α	Ito	05-20-1997	

	Examiner	Date	
1	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 6 of 22

10/689,149
10-20-2003
Miri Seiberg et al.
1616
J&J1886CIP1

U.S. PATENT DOCUMENTS

	T	U.S. Patent Document		U.S. PATENT DOCUMENTS		
Examiner	Cite	Ki	nd Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
Initials	No.1	Number (if known)	or Cited Document	mm-dd-yyyy	or relevant figures appear
		5,635,165	Α	Panitch	06-03-1997	
		5,637,316	Α	Ribier	06-10-1997	
		5,639,785	A	Kung	06-17-1997	
_		5,641,509	Α	Gross	06-24-1997	
		5,643,583	А	Voultoury	07-01-1997	
		5,643,587	Α	Scancarella	07-01-1997	
		5,643,601	Α	Gross	07-01-1997	
		5,650,166	Α	Ribier	07-22-1997	
		5,652,230	Α	Blank	07-29-1997	
		5,653,988	Α	Gerber	08-05-1997	
		5,660,853	Α	Hansenne-Richoux	08-26-1997	
		5,665,367	Α	Burger	09-09-1997	
		5,674,511	Α	Kacher	10-07-1997	
		5,676,935	Α	Mellul	10-14-1997	
		5,676,956	Α	Duffy	10-14-1997	
		5,679,374	Α	Fanchon	10-21-1997	
		5,681,571	Α	Homgren et al.	10-28-1997	
		5,681,852	Α	Bissett	10-28-1997	
		5,683,683	Α	Scafidi	11-04-1997	
		5,686,102	Α	Gross	11-11-1997	
		5,688,763	Α	Hammonds, Jr. et al.	11-18-1997	
		5,691,327	Α	Blank	11-25-1997	
		5,712,356	Α	Bothe et al.	01-27-1998	
		5,723,148	A	Love	03-03-1998	
		5,741,496	A	Khaiat	04-21-1998	
		5,753,612	Α	Mitrani	05-19-1998	
		5,755,814	Α	Berg	05-26-1998	

Examiner	Date		
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 7 of 22

10/689,149
10-20-2003
Miri Seiberg et al.
1616
J&J1886CIP1

U.S. PATENT DOCUMENTS

		U.S. Patent Document		U.S. PATENT DOCUMENTS			
Examiner	Cite No. ¹	1-141-1-	Cite Kind Coo	nd Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
Initials			Number (if known)	f known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
		5,762,916	Α	Ansmann	06-09-1998		
		5,766,628	Α	Nurnberg	06-16-1998		
		5,776,917	Α	Blank	07-07-1998		
		5,780,456	Α	Blank	07-14-1998		
		5,780,457	Α	Blank	06-14-1998		
		5,780,458	Α	Blank	07-14-1998		
		5,780,459	Α	Blank	07-14-1998		
		5,786,345	Α	Blank	07-28-1998		
		5,786,346	Α	Blank	07-28-1998		
		5,789,396	Α	Blank	08-04-1998		
		5,795,879	Α	Blank	08-18-1998		
		5,801,163	Α	Blank	09-01-1998		
	:	5,804,216	A	Terren	09-08-1998		
		5,807,545	Α	Coffindaffer	09-15-1998		
		5,824,702	A	Wei	10-20-1998		
		5,833,965	А	Sun	11-10-1998		
		5,834,013	Α	Ribier	11-10-1998		
		5,840,717	Α	Blank	11-24-1998		
		5,843,926	A	Blank	12-01-1998		
		5,863,546	Α	Swinehart	01-26-1999		
		5,869,470	Α	Blank	02-09-1999		
		5,871,743	A	Chajuss	02-16-1999		
		5,871,823	Α	Anders et al.	02-16-1999		
		5,880,314	Α	Shinomiya	03-09-1999		
		5,885,593	Α	Epstein	03-23-1999		
		5,885,596	Α	Parab	03-23-1999		
		5,885,600	Α	Blum	03-23-1999		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 8 of 22

a semester of intermedent amove it are proje-	2 delicedent et internacion diffice it displeje a tena et ite et italia.					
Application Number	10/689,149					
Filing Date	10-20-2003					
First Named Inventor	Miri Seiberg et al.					
Group Art Unit	1616					
Examiner Name						
Attorney Docket Number	J&J1886CIP1					

U.S. PATENT DOCUMENTS

		U.S. Patent Document		U.S. PATENT DOCUMENTS		
Examiner	Cite Kind Code ²			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
Initials	No. ¹	No. ¹ Number (if known)	known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
		5,885,617	A	Jordan	03-23-1999	
		5,885,948	Α	Glenn	03-23-1999	
		5,908,618	Α	Lorant	06-01-1999	
		5,912,175	Α	Wille, Jr.	06-15-1999	
		5,916,577	Α	Golz	06-29-1999	
		5,928,654	Α	Duranton	07-27-1999	
		5,928,658	Α	Kishida	07-27-1999	
		5,928,889	Α	Bakich	07-27-1999	
		5,936,052	Α	Bothe et al.	08-10-1999	
		5,942,479	A	Frankenback	08-24-1999	
		5,945,095	Α	Mougin	08-31-1999	
		5,945,109	A	Schmidt	08-31-1999	
		5,952,373	Α	Lanzendorfer	09-14-1999	
		5,958,387	Α	Bara	09-28-1999	
		5,961,980	A	Kennedy	10-05-1999	
		5,962,015	A	Delrieu	10-05-1999	
		5,962,441	Α	Blank	10-05-1999	
		5,965,153	Α	Allen	10-12-1999	
		5,972,355	A	Knight et al.	10-26-1999	
		5,981,450	Α	Fabry	11-09-1999	
		5,985,338	Α	Suh	11-16-1999	
		5,985,809	Α	Frankenback	11-16-1999	
		5,990,291	Α	Waggle	11-23-1999	
		6,004,915	Α	Elliott	12-21-1999	
		6,013,250	Α	Cannell	01-11-2000	
		6,013,255	Α	Edens	01-11-2000	
		6,017,549	Α	Knight et al.	01-25-2000	

Examiner	r Date	
Signature		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 9 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

U.S. PATENT DOCUMENTS

		U.S. Patent Document				
Examiner Initials	Cite No. ¹	Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		6,017,893	Α	Segelman	01-25-2000	
		6,018,001	А	Hiratani et al.	01-25-2000	
		6,019,962	Α	Rabe	02-01-2000	
		6,030,931	А	Vinski	02-29-2000	
		6,033,680	Α	Dixon	03-07-2000	- "
		6,045,779	Α	Mueller	04-04-2000	
		6,048,520	Α	Hoshowski	04-11-2000	
		6,051,602	Α	Bissett	04-18-2000	
		6,054,137	Α	Breton ~	. 04-25-2000	
		6,060,070	Α	Gorbach	05-09-2000	
		6,063,398	Α	Gueret	05-16-2000	
		6,080,393	Α	Liu et al.	06-27-2000	
		6,093,411	Α	Bissett	07-25-2000	
		6,096,327	Α	Lezdey et al.	08-01-2000	
		6,126,933	Α	Warne et al.	10-03-2000	
		6,180,662	B1	Lanzendorfer	01-30-2001	
		6,183,761	B1	Bissett	02-06-2001	
		6,183,762	B1	Deckers et al.	02-06-2001	
		6,261,603	В1	McElwain	07-17-2001	V
		6,323,219	B1	Costanzo	11-27-2001	
		6,433,025	B1	Lorenz	08-13-2002	-
-		6,558,656	B2	Mann	05-06-2003	
		2004/0009142	A1	Zambaux et al.	01-15-2004	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 10 of 22

a composition introduction and contract in the	
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

FOREIGN PATENT DOCUMENTS

Examiner	Cite	Foreigr	n Patent Documen	t	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant	T ⁶
Initials	No. ¹	Office ³	Number ⁴ Kin	dCode ⁵	Applicant of Cited Document	mm-dd-yyyy	figures appear	<u> </u>
		AU	724988	B2	Genentech, Inc.	05-29-1998	=WO 98/19700	
		CN	1094279	Α	Wang	11-02-1994	English Abstract	No
		EP	0 273 202	A2	Van Scott et al.	07-06-1988		
		EP	0 393 532	A2	Schering Corporation	10-24-1990		
		EP	0 421 021	A1	Mucos Emulsionsgesellschaft	04-10-1991		Yes
		EP	0 473 502	A1	Shiseido Co. Ltd.	03-04-1992		
		EP	0 508 886	A1	Digital Equipment Corporation	10-14-1992	=JP 5114905	
		ΕP	0 574 352	A1	Ciba-Geigy AG	12-15-1993		
		ΕP	0 643 083	A1	Essilor International	03-15-1995	English Abstract &d Claims from B1 Doc	No
		EΡ	0 643 960	A1	Laboratoire de Biologie Vegetale Yves Rocher	03-22-1995	=US 5,741,496	No
		EP	0 655 470	A1	Ciba-Geigy AG	05-31-1995	=US 5,712,356 & 5,936,052	No
		EP	0 661 037	A1	L'Oreal	07-05-1995	=US 5,629,015	No
		EP	0 707 851	A2	Fockerman et al.	04-24-1996		
		EP	0 713 106	A1	Menicon Co., Ltd.	05-22-1996		
		EP	0 758 687	A1	Ciba-Geigy AG	02-19-1997		
		EP	0 774 249	A2	Unilever PLC	05-21-1997		
-		EP	0 811 595	A1	Mitsui Toatsu Chemicals, Inc.	12-10-1997		ļ
		EP	0 814 116	A1	Huls AG	12-29-1997	=US 5,871,823	No
		EP	0 963 761	A1	J&J Vision Products	12-15-1999	VTN0410	
		EP	1 074 240	A2	J&J Consumer Products Inc.	02-07-2001	JBP510	
		EP	1 077 063	A2	J&J Consumer Products Inc.	02-21-2001	JBP0402	
		EP	1 192 938	A2	J&J Consumer Products Inc.	04-03-2002	JBP0523	
		EP	1 236 402	A2	J&J Consumer Products Inc.	09-04-2002	J&J2001	
		EP	1 236 465	A2	J&J Consumer Products Inc.	09-04-2002	J&J2002	
		FR	2 596 986	A1	Sederma SA (FR)	10-16-1987	English Abstract	No
		FR	2 641 696	A1	Sederma SA (FR)	07-20-1990	English Abstract	No
		FR	2 685 202	A1	Sederma SA (FR)	06-25-1993	English Abstract	No

 Examiner	Date
 Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 11 of 22

Under the Paperwork Reduction Act of 1995, no persons are required to respond	to a collection of information unless it displays	
form 1449A/PTO	Application Number	10/689,149
	Filing Date	10-20-2003
ORMATION DISCLOSURE	First Named Inventor	Miri Seiberg et al.
TEMENT DV ADDI ICANT	Group Art Unit	1616
TEMENT BY APPLICANT	Examiner Name	
(use as many sheets as necessary) Sheet 11 of 22	Attorney Docket Number	J&J1886CIP1

FOREIGN PATENT DOCUMENTS

Examiner	Cite	Foreigr	n Patent Documen	t -	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant	T ⁶
Initials	No.1	Office ³	Number⁴ Kin	dCode ⁵	Applicant of Cited Document	mm-dd-yyyy	figures appear	<u> </u>
		FR	2 803 747	A1	Laboratoires Pharmascience	07-20-2001		Yes
		FR	2 811 226	A1	Clarins Laboratoires	01-11-2002		Yes
		JP	1096106	Α	Shiseido Company, Ltd	04-14-1989		Yes
		JP	3127713	Α	Sansho Pharmaceutical et al.	05-30-1991		Yes
_		JP	4169514	Α	Shiseido Company, Ltd.	06-17-1992		Yes
		JP	5015574	Α	Japan Atom Energy Res Inst, et al.	01-26-1993		Yes
		JP	5114905	Α	Digital Equipment Corp.	05-07-1993	=EP 0 508 886	No
		JP	5213729	Α	Kao Corporation	08-24-1993		Yes
		JP	5246932	Α	KK Japan Hypo	09-24-1993	5.5.	Yes
		JР	5320024	Α	Dowa Mining Co. Ltd.	12-03-1993		Yes
		JP	5320061	Α	Soken Company, Ltd.	12-03-1993		Yes
		JP	6145061	Α	Fuji Seiyu KK	05-24-1994	English Abstract	No
		JP	6192085	Α	Inada Y	07-12-1994	English Abstract	No
		JP	7010772	Α	Fuji Seiyu KK	01-13-1995	English Abstract	No
		JP	7196527	Α	Morinaga Milk Ind. Co. Ltd.	08-01-1995	English Abstract	No
		JР	7196529	Α	Morinaga Milk Ind. Co. Ltd.	08-01-1995	English Abstract	No
		JP	7304655	Α	Kikkoman Corp.	11-21-1995		Yes
		JP	8012560	Α	Shiseido Company, Ltd.	01-16-1996		Yes
		JP	8020597	Α	Meiji Pharmaceutical Company, Ltd.	01-23-1996		Yes
		JP	8040824	Α	Nonogawa Shoji:KK	02-13-1996	English Abstract	No
		JР	8059450	Α	Kose Corporation	03-05-1996	English Abstract	No
		JP	8099891	Α	Pola Chemical Industrial Company, Ltd.	04-16-1996		Yes
		JP	8143442	Α	Kikkoman Corp.	06-04-1996	English Abstract	No
		JP	8333260	Α	Kaminomoto Honpo:KK	12-17-1996	English Abstract	No
		JP	9025212	Α	Shiseido Co. Ltd.	01-28-1997		Yes
-		JР	9025214	А	Shiseido Co. Ltd.	01-28-1997	<u> </u>	Yes
		JP	9059166	Α	Kikkoman Corp.	03-04-1997	English Abstract	No

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 12 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1
	1

FOREIGN PATENT DOCUMENTS

Examiner	Cite	Foreigr	Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant	T ⁶
Initials	No. ¹	Office ³	Number ⁴ Kind	lCode ⁵	Applicant of Cited Document	mm-dd-yyyy	figures appear	
		JP	9077638	Α	Art Beauty Clinic KK	03-25-1997	English Abstract	No
		JP	9176033	Α	Pigeon Corp.	07-08-1997	English Abstract	No
		JP	11346695	Α	National Food Res. Inst. Ryookoku Shoji KK	12-21-1999		Yes
		٩t	58225003	Α	Ichimaru Fuarukosu KK	12-27-1983		Yes
		JP	58225004	Α	Ichimaru Fuarukosu KK	12-27-1983	English Abstract	No
		JP	59187756	Α	Erika KK	10-24-1984	English Abstract	No
		JP	62036304	Α	Kashiwa Chemical Industries	02-17-1987		Yes
		JP	63068512	Α	Awase Kosufua Company Ltd., et al.	03-28-1988		Yes
		JP	63096120	Α	Matsuura Pharmaceutical Company	04-27-1988		Yes
		JP	63227515	Α	New Japan Chemical Engineering KK	09-21-1988		Yes
		JP	63316711	Α	Nonogawa Shoji Company, Ltd.	12-26-1988		Yes
		JP	2000302678	Α	Crescendo Corp.	10-31-2000	English Abstract	No
		KR	92-8851	B1	Park	10-01-1992		Yes
		KR	92-8853	В	Song	10-10-1992	English Abstract	No
		RU	2066992	C1	Ostroumova Nadezhda Mikhajlovna	09-27-1996		Yes
		wo	87/07838	A1	Societe Bio Serae Sarl	12-30-1987	=US 4,978,528	No
		wo	91/04283	A1	Chang et al.	04-04-1991		
		wo	91/07166	A1	Washington State University	05-30-1991		
		wo	92/09639	A2	Bausch & Lomb Incorporated	06-11-1992		
		wo	92/09650	A1	Bausch & Lomb Incorporated	06-11-1992		
		wo	94/06485	A1	Ciba-Geigy AG	03-31-1994		
		wo	95/04609	A1	Ciba-Geigy AG	02-16-1995		
		wo	95/09002	A1	University of Pennsylvania	04-06-1995		
		wo	95/09011	A1	University of Pennsylvania	04-06-1995		
		wo	95/24885	A1	Handelman	09-21-1995		
		wo	96/09806	A2	Handelman	04-04-1996		
		wo	96/19483	A1	Biochem Pharma Inc.	06-27-1996		

Examiner	Date	
Lamine	20.0	1
Signature	Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

on of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 13 of 22

a collection of information unless it displays	Traile Civil Control Herriber.
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docum	ent	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T⁵
		wo	96/19491	A1	Biochem Pharma Inc.	06-27-1996		
		wo	96/24371	A1	Phairson Medical Inc.	08-15-1996		
		wo	96/24392	A1	Fidia Advanced Biopolymers	08-15-1996		
		wo	96/30035	A1	Molecumetrics Ltd.	10-03-1996		
		wo	96/30396	A1	Molecumetrics Ltd.	10-03-1996		
		wo	96/31194	A2	J&J Consumer Products Inc.	10-10-1996	JBP0319	
		wo	96/37497	A1	Biochem Pharma Inc.	11-28-1996		
		wo	96/40121	A1	Taisho Pharmaceutical Co. Ltd.	12-19-1996		Yes
		wo	96/40199	A1	University of Pennsylvania	12-19-1996		<u></u>
		wo	97/11033	A2	Nord-Beton GMBH	03-27-1997	English Abstract	No
		wo	97/18904	A1	Massachusetts Institute of Technology	05-29-1997		
		wo	97/35998	A1	Trustees of Boston University	10-02-1997		
		wo	97/39733	A1	The Procter & Gamble Company	10-30-1997		
		wo	98/01107	A1	Industria E Comercio de Cosmeticos Natura	01-15-1998		
		wo	98/02134	A1	J&J Consumer Products Inc.	01-22-1998	J&J1616	
		wo	98/02138	A1	Industria E Comercio de Cosmeticos Natura	01-22-1998		
		wo	98/05333	A1	Molecumetics Ltd.	02-12-1998		
		wo	98/08503	A1	Novogen Research Pty. Ltd.	03-05-1998		
		wo	98/09987	A1	Biochem Pharma, Inc.	03-12-1998		
		wo	98/17246	A1	ROC	04-30-1998		
		wo	98/33089	A1	Menicon Co., Ltd.	07-30-1998	=US 6,018,001	No
		wo	98/49153	A1	Novogen Inc.	11-05-1998		
		wo	99/09065	A1	Eberhard-Karls-Univ.	02-25-1999		Yes
		wo	99/15917	A1	Novartis AG	04-01-1999		
		wo	99/24003	A1	The Procter & Gamble Company	05-20-1999		
		wo	99/30729	A1	J&J Consumer Products Inc.	06-24-1999	JBP0438	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 14 of 22

a rana cinib denadi nambon.
10/689,149
10-20-2003
Miri Seiberg et al.
1616
J&J1886CIP1

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docum	nent	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number⁴	KindCode ⁵	Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶
		wo	99/36050	A1	Novogen Research Pty. Ltd.	07-22-1999		
		wo	99/57178	A1	Bausch & Lomb Incorporated	11-11-1999		
		wo	00/15188	A1	Sederma	03-23-2000		Yes
		wo	00/43049	A1	Pharmacia & Upjohn Company	07-27-2000		
		wo	00/51554	A2	Johns Hopkins University	09-08-2000		
		wo	00/62740	A2	The Procter & Gamble Company	10-26-2000		
		wo	00/62741	A2	The Procter & Gamble Company	10-26-2000		
		wo	00/62743	A2	The Procter & Gamble Company	10-26-2000		
		wo	00/62744	A2	The Procter & Gamble Company	10-26-2000		
		wo	00/62745	A2	The Procter & Gamble Company	10-26-2000		
		wo	00/69404	A1	The Procter & Gamble Company	11-23-2000		
		wo	00/69406	A1	The Procter & Gamble Company	11-23-2000		
		wo	00/69407	A1	The Procter & Gamble Company	11-23-2000		
,		wo	00/69408	A1	The Procter & Gamble Company	11-23-2000		
		wo	01/34099	A1	J&J Consumer Products Inc.	05-17-2001	JBP0518	
		wo	01/35920	A1	Hindustan Lever Limited	05-25-2001		
		wo	02/07697	A1	Cognis France S.A.	01-31-2002	=US 2004/009142	Yes

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		"A Combined Soybean Crushing-Deordorizing System that Yields 100-200 Mesh Powder for Food Additive Use has been Developed by SHINYU ZOKI CO. LTD. And MITSUBISHI RAYON ENGINEERING LTD.", <i>Tech Times</i> , pp 10 (1978).	
		"Avon's Anew Positivity Trio Targets Menopausal Women", The Rose Sheet, February 28, 2000, page 8	
		"CaspACE™ Assay System, Colorimetric", Product Improvements, Neural Notes Volume V, Issue 1, p 13 (1999) PROMEGA CORPORATION.	
		"Elhibin®" Product Brochure, PENTAPHARM, Centerchem, Inc., Stamford, CT, publicly available prior to February 28, 2001.	

		_
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 15 of 22

Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

	Γ -	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		"EnzChek® Protease Assay Kits" Product Information, MP06638, pp 1-4, Revised February 25, 2001, MOLECULAR PROBES, Eugene, OR.	
		"Flavosterone S (Soybean Extract Contained Iso-Flavone", ICHIMARU PHARCOS CO., LTD. pp 11-13 (December 22, 1998).	
		"Isoral" Soybean power makes your skin clear and moist!" – Brochure, publicly available prior to February 28, 2001.	
		"Lipoxydase Code 411784", Lipoxydase File April 1999, A LIBiol Body Care Composition.	
		"Nudit Advertisement", publicly available prior to February 28, 2001.	
		"Patent Abstracts - Gastric Juice for Antiaging 1997".	
		"Patent Abstracts - Plant extracts for skin whitening", publicly available prior to February 28, 2001.	
		"Patent Abstracts - Soybeans for skin pigmentation 1997".	
		"Patent Abstracts - Soybeans for skin whitening 1997".	
		"Patent Abstracts of requested patent titles 1996".	
		"Patent List - Thrombin Inhibitors: List of Relevant Patent Applications as of July 8, 1998, and October 1, 1996."	
		"Plant Extract Containing Female Hormone-Like Isoflavones - Flavosterone", leaflet from ICHIMARU PHARCOS issued March 7, 1997	
		"Product for Damaged hair by Bristol-Myers-Squibb", (Abstract) publicly available prior to February 28, 2001.	
		"RQ1 RNase-Free DNASE", PROMEGA CORPORATION, Technical Bulletin No. 518, pp 1-4, February 2000, Part#TB518, Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711-5399	
		"Soy Protein Prevents Skin Tumors From Developing in Mice", Gene Therapy Weekly, ISSN 1078-2842, pp 21 (November 8, 2001).	
		"Soy Therapy", www.wiseessentials.com/soytherapy.html (email from Jue-Chen Liu, Ph.D. to Cunero et al dated April 13, 2000) WISE ESSENTIALS.	
		"Soybean Technology Improves Skin", Allured's Cosmetics & Toiletries Magazine, Vol. 115, No. 3, March 2000, p 22.	
		"Superscript II Reverse Transciptase" protocol published by Gibco-BRL (now Life Tech Inc.) April 1992	
		"The Joy of Soy", www.wheat-grass.com/851_oral_liquid.shtml, WHEATGRASS EXPRESS, INC., 1996.	
		"ThermoScript™ RNase H-Reverse Transcriptase", INVITROGEN™ LIFE TECHNOLOGIES, www.invitrogen.com/content.cfm, Invitrogen Corporation, 2001.	
		"Whitening with Soybean? HR has launched "Future White" in Japan", Helena Rubinstein, publicly available prior to February 28, 2001.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 16 of 22

a collection or information unless it displays	a valid OND control number.
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

	T	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's Initials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		AHRENS ET AL, "Photocarcinogenesis and Inhibition of Intercellular Adhesion Molecular I	
		Expression in Cells of DNA-Repair-Defective Individuals", <i>Proc. National Academy of Sciences</i> , Vol. 94 (1997) pp 6837-6841.	
		BADASH ET AL, "Effect of Gamma Irradiation of Field and Storage Fungi of Wheat, Maize and Soybean", Chemie Mikrobiologie Technologie der Lebensmittel (1992).	
		BALSAM ET AL, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp 32-43 (1972).	
		BALSAM ET AL, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp 72-73 (1972).	
	-	BARBUCH ET AL, "The Use of Thermospray Liquid Chromatography/Tandem Mass Spectrometry for the Class Identification and Structural Verification of Phytoestrogens in Soy Protein Preparations", <i>Biomedical and Environmental Mass Spectrometry</i> , Vol. 18 (1989) pp 973-977.	
		BAREL ET AL, "Suction Method for Measurement of Skin Mechanical Properties: The Cutometer®", Chapter 14.3, pp 335-340, <i>Handbook of Non-Invasive Methods and the Skin</i> , Jorgen Serup and G.B.E. Jemec (1995).	
		BATISTA ET AL, "Primary Structure of a Kunitz-Type Trypsin Inhibitor From Enterolobium Contortisiliquum Seeds", <i>Phytochemistry</i> , Vol. 41, No. 4, (1996) pp 1017-1022.	
		BENSHIMOL, "The Biochemistry And Nutrition Group: 30 Years Of Research In A Developing Country", <i>Archivos LatinoAmericanos De Nutrician</i> , Vol. 44, No. 4-S, pp 6-S-9-S (1994).	
		BILLINGS ET AL, "A Growth-Regulated Protease Activity that is Inhibited by the Anticarcinogenic Bowman-Birk Protease Inhibitor", Pro. Natl. Acad. Sci., Vol. 89, pp 3120-3124 (1992).	
		BIRK, "Protein Proteinase Inhibitors in Legume Seeds – Overview", Archivos Latinoamericanos de Nutricion, Vol. 44, No. 4-S (1994) pp 26-S-30-S.	
		BIRK, "The Bowman-Birk Inhibitor - Trypsin- and Chymotrypsin-Inhibitor from Soybeans", Int. J. Peptide Protein Res., Vol. 25, pp 113-131 (1985).	
		BLACKHEART ET AL, "Ligand Cross-Reactivity Within the Protease-Activated Receptor Family", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 28, pp 16466-16471 (1996)	
		BONIFACINO ET AL, "Electrophoresis and Immunoblotting", Chapter 6, pp 6.0.1-6.6.1, Current Protocols in Cell Biology, copyright 2000 by John Wiley & Sons, Inc.	
		BRASS ET AL, "Protease-Activated G Protein Coupled Receptors On Human Platelets and Endothelial Cells", F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart), Vol. 78, No. 1, pp 234-241 (1997).	
		CHOMCZYNSKI ET AL, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," <i>Analytical Biochemistry</i> , Vol. 162, pp 156-159 (1987).	
		CLARK ET AL, "Tryptase Inhibitors Block Allergen-induced Airway and Inflammatory Responses in Allergic Sheep", <i>American Journal of Respiratory and Critical Care Medicine</i> , Vol. 152, pp 2076-2083, 1995.	
		CONNOR ET AL, "Depletion of Cutaneous Glutathione By Ultraviolet Radiation", Photochemistry and Photobiology, Vol. 46, No. 2, pp 239-245 (1987).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 17 of 22

a conection of information unicos it displays a	Taile Citiz Contact Hamber.
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
No.	publisher, city and/or county white publisher. The St. Subsity: Tripontide	
	COSTANZO ET AL, POLERI THIOTHOM HINDILORS HIS Activated Carbonyl Group' I Med	
	Of the Value Analogue's based on A helefocycle Activated Carbonyl Group , J. Med.	
	Chem., Vol. 39, 1996, pp 3039-3043.	
-		
	1994, pp 9200-9202.	
	COVELLI ET AL, "Diazepam Inhibits Phagocytosis and Killing Exerted by Polymorphonuclear	
	Cells and Monocytes From Healthy Donors", Abstract, Immunopharmacology and	
	Immunotoxicology, Vol. 11, No. 4 (1989) pp. 701-714, copyright © 1989 by Marcel Dekker, Inc.	
	CUNNIFF, "Official Methods of Anaysis of AOAC International", 16" Adition, 5" Revision (1999)	
	AOAC International.	
	DE SEIDL, "Interaction of Proteases with Legume Seed Inhibitors, Molecular Features",	
	Archivos Latinoamericanos de Nutricion, Vol. 44, No. 4-S (1994) pp 21-S - 25-S.	
	DERIAN ET AL. "Differential Regulation of Human Keratinocyte Growth and Differentiation by a	
	Novel Family of Protease-activated Receptors": Cell Growth & Differentiation, Vol. 8, pp 743-	
	DEWITT ET AL "Astrocytes Regulate Microglial Phagocytosis Of Senile Plague Cores Of	
	Alzheimer's Disease" Experimental Neurology Vol. 149 Article No. EN976738 (1998) pp. 329-	
	DOOLITTLE "Proteins" Reading from Scientific American - The Molecules of Life Chapter 4	-
	DODING "The Pole Of Neutrophil Electors in Chronic Inflammation" American Journal of	
	Bookings, The Role Of Neutrophili Liastase in Chronic Inflammation, American Countries of Critical Core Medicine, Vol. 150, 1904, pp. 8114 - 8117	
	Respiratory and Chicar Care Medicine, vol. 190, 1994, pp 0114 - 0117.	
	DUNAEVSKY ET AL, TWO GROUPS OF FROTEASE INHIBITIONS FUNCTIONALLY IN DUCKWIEST	
	Seeds , sobalsminshu-uac.jp/contents/105.ntml, publicly available pilot to reprint year.	
	DUNAEVSKY ET AL, "Isolation and Properties of Antionic Protease Infinitions from buckwitean	
	•	
	1976).	
	and Metabolism, Vol. 15, No. 2, pp 319-339 (May 1986).	
	Hexarelin in the Rat", <i>J. Pharm. Pharmacol.</i> (1998) Vol. 50, pp 467-473.	
	FIMIANI ET AL, "Mid-Dermal Elastolysis; An Ultrastructural and Biochemical Study", Arch.	
	Dermatol Res., Vol. 287, (1995) pp 152-157.	
	FOX ET AL. "Identification Of Potential Activators Of Proteinase-Activated Receptor-2".	
	Federation of European Biochemical Societies, FEBS Letters 417 (1997) pp 267-269.	
	GALVEZ ET AL "Chemopreventive Property of a Soybean Pentide (Lunasin) That Binds to	
	Descendated Histories and Inhibits Acetylation" Cancer Research Vol. 61 No. 20 no 7473-	
	CRANT TUELLE "Deviced noted Disease Dispates and Immuno Despates A Pavious Of	
ĺ	Current Concepts", Periodontal Abstracts, Vol. 44, No. 3, 1996, pp 69-77.	
	Cite No.1	No.¹ COSTANZO ET AL, "Potent Thrombin Inhibitors That Probe The S1 Subsite: Tripeptide Transition State Analogues Based On A Heterocycle Activated Carbonyl Group", <i>J. Med. Chem.</i> , Vol. 39, 1996, pp 3039-3043. COUGLIN, "Protease Activated Receptors Start A Family", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, 1994, pp 9200-9202. COVELLI ET AL, "Diazepam Inhibits Phagocytosis and Killing Exerted By Polymorphonuclear Cells and Monocytes From Healthy Donors", Abstract, <i>Immunopharmacology and Immunotoxicology</i> , Vol. 11, No. 4 (1989) pp. 701-714, copyright © 1998 by Marcel Dekker, Inc. CUNNIFF, "Official Methods of Anaysis of AOAC International", 16 th Adition, 5 th Revision (1999) AOAC International. DE SEIDL, "Interaction of Proteases with Legume Seed Inhibitors, Molecular Features", <i>Archivos Latinoamericanos de Nutricion</i> , Vol. 44, No. 4-S (1994) pp 21-S - 25-S. DERIAN ET AL, "Differential Regulation of Human Keratinocyte Growth and Differentiation by a Novel Family of Protease-activated Receptors"; <i>Cell Growth & Differentiation</i> , Vol. 8, pp 743-749, July 1997. DEWITT ET AL, "Astrocytes Regulate Microglial Phagocytosis Of Senile Plaque Cores Of Alzheimer's Disease", <i>Experimental Neurology</i> , Vol. 149, Article No. EN976738 (1998) pp 329-340. DOOLITTLE, "Proteins", <i>Reading from Scientific American - The Molecules of Life</i> , Chapter 4, pp 38-47 (1985). DORING, "The Role Of Neutrophil Elastase In Chronic Inflammation", <i>American Journal of Respiratory and Critical Care Medicine</i> , Vol. 150, 1994, pp S114 - S117. DUNAEVSKY ET AL, "Two Groups of Protease Inhibitors Functionally Active in Buckwheat Seeds", soba. shinshu-uac.jpicontents/1016.html, publicly available prior to February 28, 2001. DUNAEVSKY ET AL, "Hair", <i>Journal of Investigative Dermatology</i> , Vol. 67, No. 1, pp 98-105 (July 1976). EBLING, "Hair Follicles and Associated Glands as Androgen Targets", <i>Clinics in Endocrinology and Metabolism</i> , Vol. 15, No. 2, pp 319-339 (May 1986). FAGERHOLM ET AL, "The Effect of a Drug-delivery System Consisting of

Examir	er	Date	
Signati	re	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 18 of 22

a consequent of mineral and a consequence of the co	
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

	,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	1
Examiner's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Examiners Initials*	No.1	publisher, city and/or country where published	
		GREENBERGER, "Immunologic Aspects Of Lung Diseases And Cystic Fibrosis", JAMA, Vol.	
_		278. No. 22 (1997) pp 1924-1930.	<u> </u>
		GUO ET AL, "A Serine Protease From Suspension-Cultured Soybean Cells", Phytochemistry,	
		Vol. 47, No. 4 (1998) pp 547-553.	ļ
	}	HACHIMI ET AL, "Do Microglial Cells Phagocyte The B/A4-Amyloid Senile Plaque Core of	
	ļ	Alzheimer Diesease?", C.R. Academy of Science, Paris, Sciences de la vie/Life sciences, Vol.	
		317, 1994, pp. 445-451.	 -
		HACKER, "Common Disorders Of Pigmentation - When are more than cosmetic cover-ups	
		required?", Postgraduate Medicine, Vol. 99, No. 6, 1996, pp 177-186. HAFEZ ET AL, "Effects of Gamma Irradiation on Proteins and Fatty Acids of Soybean", Journal	
		of Food Science, Vol. 50 (1985) pp 1271-1274.	
		HAMADA, "Evaluation of the Effects of Hair Re-growth Agents on Lengthening the Anagen	
		Phase Period and Blockade of Anagen phase-Catagen phase Transformation", J. Soc. Cosmet.	Yes
		Chem. Japan, Vol. 31, No.4 (1997) pp 413-419.	
		HANADA ET AL, "Photoprotective Effect of Esterified Glutathione Against Ultraviolet B-Induced	
		Sunburn Cell Formation in the Hairless Mice", The Journal of Investigative Dermatology, Vol.	
	1	108, No. 5, pp 727-730 (1997).	
_		HASLER ET AL, "Nutrition Communique, Soy: Just a Hill of Beans?", Journal of Women's	
		Health, Vol. 7, No. 5 (1998) pp 519-523.	<u> </u>
		HATTORI ET AL, "Effects of sup.60 Co- gamma-rays on Defatted Soybean Powder", Food	
		Irradiation, Vol. 3, No. 1, pp 104-110 (1968).	ļ
		HAYASHI ET AL, "Inhibition of Serine Proteases of the Blood Coagulation System by Squash	
	ļ <u>.</u>	Family Protease Inhibitors", J. Biochem., Vol. 116, No. 5, pp 1013-1018 (1994).	
		HENDRICH ET AL, "Defining Food Components as New Nutrients", American Institute of	
		Nutrition, Food Composition (1994) pp 1789S-1792S. HOFF ET AL, "Macrophage Uptake Of Cholesterol-Containing Particles Derived From LDL and	
		Isolated From Atherosclerotic Lesions", <i>European Heart Journal</i> , Vol. 11, Supplement E, 1990,	
		pp 105-115.	
	-	HOLLENBERG ET AL, "Proteinase-Activated Receptor-2 in Rat Aorta: Structural Requirements	
		for Agonist Activity of Receptor-Activating Peptides", Molecular Pharmacology, Vol. 49, pp	
		229-233 (1996).	
		ITAMI ET AL, "Mechanism of Action of Androgen in Hair Follicles", Journal of Dermatological	
		Science, 7 Suppl., S98-S103 (July 1994).	<u> </u>
		JIMENEZ ET AL, "Mammalian Tyrosinase: Biosynthesis, Processing and Modulation By	
		Melanocyte Stimulating Hormone", Proc. Natl. Acad. Sci. USA (1988), Vol. 85, pp 3830-3834.	<u> </u>
		JIMENEZ ET AL, "Specific Identification of an Authentic Clone for Mammalian Tyrosinase", The	
		Journal of Biological Chemistry, (1989) Vol. 264, No. 6, pp 3397-3403.	├
		JINGTIAN ET AL, "Studies of Soy Sauce Sterlization and its Special Flavour Improvement by	
		Gamma-Ray Irradiation", Radiation Physics and Chemistry, Vol. 31, Nos 1-3, pp 209-213	
		(1988) KEETON ET AL, "The Chemistry of Life", <i>Biological Science</i> , Fourth Edition, Chapter 3, pp 66-	1
		67 (1986)	
	<u> </u>	07 (1990)	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 19 of 22

a concouch of information amode it displays	
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KENNEDY ET AL, "Prevention of Carcinogenesis by Protease Inhibitors", Cancer Research,	
		Vol. 54, No. 7 (Suppl), pp 1999s-2005s (April 1, 1994).	
	1	KENNEDY, "The Evidence for Soybean Products as Cancer Preventive Agents", The Journal of	
		Nutrition, Vol. 125, No. 3 Suppl, pp 733s-743s (March 1995).	
		KENNEDY, "Chemopreventive Agents: Protease Inhibitors," <i>Pharmacol. Ther.</i> , Vol. 78, No. 3, pp 167-209, 1998, Copyright 1998 Elsevier Science Inc.	
	-	KENNEDY, "The Bowman Birk Inhibitor from Soybeans As An Anticarcinogenic Agent",	
		American Journal of Clinical Nutrition, Vol. 68(suppl), pp 1406S-1412S (1998).	
		KOVACS ET AL, "Effect of Irradiation and Dielectric Heating on Soybean Ultrastructure,	
		Trypsin Inhibitor, and Lipoxygenase Activities", Food Structure, Vol. 10, pp 217-227 (1991)	
		LAM ET AL, "Combined Effect of Irradiation and Dielectric Heating on Chemical Properties of Soybeans", 7th Symp. On Radiation Chemistry, pp 477-483 (1990)	
	-	LIMTRAKUL ET AL, "Suppressive Effect of Soybean Milk Protein on Experimentally Induced	-
		Skin Tumor in Mice", Life Sciences, Vol. 53 (1993) pp 1591-1596.	
•		LIU ET AL, "Aqueous Ethanol Extraction of Soybean Trypsin Inhibitors and Characterization of	
		a Calcium-Sensitive Fraction", Journal of Food Biochemistry, Vol. 15 (1991) pp 159-168.	
-		LIU, "Chemistry And Nutritional Value Of Soybean Components", in Soybeans, Chemistry,	
		Technology and Utilization, pp. 32-35 (copyright © 1997 by Chapman & Hall).	
		MACFARLANE ET AL, "Refractory Periodontitis Associated With Abnormal Polymorphonuclear Leukocyte Phagocytosis and Cigarette Smoking", <i>J. Peridontal</i> , Vol. 63, No. 11, November	
		1992, pp 908-913. MAES ET AL, "Leukocytosis, Monocytosis and Neutrophilla: Hallmarks Of Severe Depression",	
		J. Psychiat. Res., Vol. 26, No. 2 (1992) pp 125-134.	
		MAHONEY ET AL, "Amino Acid Sequence and Secondary Structural Analysis of the Corn Inhibitor of Trypsin and Activated Hageman Factor", <i>Journal of Biological Chemistry</i> , Vol 259, No. 13 (July 10, 1984) pp 8412-8416.	
		MCADAMS ET AL, "Neutrophil and Monocyte Phagocytosis In Depressed Patients", <i>Prog. Neuro-Psychopharmacol & Biol. Psychiat</i> (1993) Vol. 17, pp 971-984.	
		McCutcheon's Emulsifiers and Detergents 1986, North American Edition, McCutcheon Division, Mc Publishing Co., Glen Rock, New Jersey, pp 317-324 (1986).	
		MEISTER, "Glutathione, Ascorbate, and Cellular Protection", Cancer Research, Vol. 54, pp 1969s-1975s (1994).	
	-	Merck Index (12th Edition), Edited by Susan Budavari (1996) Thrombin., entry 9525, p 1601.	
		Merck Index (12th Edition), Edited by Susan Budavari (1996) Trypsin, entry 9926, p 1669.	
		MERCOLA, "Concerns Regarding Soybeans", www.rheumatic.org/soy.htm, publicly available prior to February 28, 2001.	
		MESSINA, "Soy Intake and Cancer Risk: A Review of the In Vitro and In Vivo Data", Nutrician and Cancer, Vol. 21, No. 2 (1994) pp 113-131.	
		MEZEI ET AL, "Liposomes-A Selective Drug Delivery System for the Topical Route of Administration: Gel Dosage Form", Journal of Pharmaceutics and Pharmacology, Vol. 34	
		(1982), pp 473-474.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

rmation unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 20 of 22

a collection of insormation divisor it displays a	TEND COND CONTROL TO A TO CONTROL
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1
-	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MEZEI, "Liposomes as a Skin Drug Delivery System", <i>Topics in Pharmaceutical Sciences</i> (D. D. Breimer and P. Speiser, eds.,), Elsevier Science Publishers B. V., New York, N.Y., 1985, pp 345-358.	
		MIYAGI ET AL, "Trypsin Inhibitor Activity in Commercial Soybean Products in Japan", J. Nutr. Sci. Vitaminol (1997) Vol. 43, pp 575-580.	
		MOLINARI ET AL, "Inhaled Tryptase Causes Bronchoconstriction in Sheep Via Histamine Release", American Journal of Respiratory and Critical Care Medicine, Vol. 154, pp 649-653, 1996.	
		MOLINO ET AL, "Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2", Journal of Biological Chemistry, Vol. 272, No. 7, 14 Feb 1997, pp 4043-4049.	
		MORITA ET AL, "Partial Purification and Characterization of a Novel Soybean Protease Which is Inhibited by Kunitz and Bowman-Birk Trypsin Inhibitors", <i>J. Biochem.</i> , Vol. 119, No. 4, 1996, pp 711-718.	
		MULIMANI ET AL, "Effect of Heat Treatments on Trypsin/Chyomotrypsin Inhibitor Activity of Red Gram (Cajanus Cajan L.)", <i>Plant Foods for Human Nutrition</i> , Vol. 46, No. 2, (1994) pp 103-107.	
		MULIMANI ET AL, "Effects Of Heat Treatment and Germination On Trypsin and Chymotrypsin Inhibitory Activities In Sorghum (Sorghum Bicolor (L.) Moench) Seeds", <i>Plant Foods for Human Nutrition</i> , Vol. 44, No. 3 (1993) pp 221-226.	
		MURPHY, "Phytoestrogen Content of Processed Soybean Products", Food Technology, Vol. 1, pp 60-64 (1982).	
		MUSCLOW ET AL., "Fluorescence Assay To Monitor Phagocytosis By Blood-Clot Derived Polymorphonuclear Leucocytes, 1 Study Of Patients With Diabetes And Phagocytosis Of Different Staphyloccoccal Species", <i>Cytobios</i> , Vol. 65, 1991, pp 15-24 (published and (C) 1991 by the Faculty Press, Cambridge, Great Britain).	
		MYSLIBORSKI ET AL, "Therapy for Acne Vulgaris", Comprehensive Therapy, Vol. 7, No. 1, pp 13-16 (January 1981).	
		NIEMIÈC ET AL., "Influence of Nonionic Liposomal Composition on Topical Delivery of Peptide Drugs into Pilosebaceous Units: An in Vivo Study Using the Hamster Ear Model", Pharmaceutical Research, Vol. 12, No. 8, 1995, pp 1184-1188.	
		ODANI ET AL, "Studies on Soybean Trypsin Inhibitors. XIII. Preparation and Characterization of Active Fragments from Bowman-Birk Proteinase Inhibitor", <i>Journal Biochem.</i> , Vol. 83, No. 3, pp 747-753 (1978).	
		ODANI ET AL., "Wheat Germ Trypsin Inhibitors. Isolation and Structural Characterization of Single-Headed and Double-Headed Inhibitors of the Bowman-Birk Type", <i>J. Biochem.</i> , Vol. 100, pp 975-983 (1986).	
		Official Compendia of Standards, USP 24 USP/NF 19", US Pharmacopeial Convention, Inc. 2000 (Board of Trustees, US Pharmacopieal Convention, Inc.)	
		OGAWA, "Current Problem of Research on Hair Growth Mechanisms and Hair Growth Promotors", Fragrance Journal, Vol. 5, pp 1-5 (1989)	
		ORLOW ET AL, "Subcellular Distribution Of Tyrosinase and Tyrosinase-Related Protein-1: Implications For Melanosomal Biogenesis", <i>The Journal of Investigative Dermatology, Inc.</i> , Vol. 100, No. 1, January 1993, pp 55-64.	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 21 of 22

a conection of information unices it displays t	Talla Cilib della di Harribor.
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

	ī	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	ĺ	QUILLIEN ET AL, "Trypsin Inhibitor Polymorphism: Multigene Family Expression and	
		Posttranslational Modification", Journal of Protein Chemistry, Vol. 16, No. 3 (1997) pp 195-203.	_
-		REINER, "Altered Cell Signaling and Mononuclear Phagocyte Deactivation During	
		Interacellular Infection", Immunology Today, Vol. 15, No. 8 (1994) pp 374-381.	
		RIPKA ET AL, "Chapter 8: Antithrombotics/Serine Protease", Covads International, San Diego,	
	1	CA, publicly available prior to February 28, 2001.	
		ROBERT ET AL, "Cell-Matrix Interactions In The Genesis Of Arteriosclerosis and Alateroma,	
		Effect of Aging", Laboratorie de Biologie du Tissu Conjonctif, Annals New York Academy of	
		Sciences, 1992, pp 331-341.	
		SANTULLI ET AL, "Evidence for the Presence of a Protease-Activated Receptor Distinct from	
	-	the Thrombin Receptor in Human Keratinocytes", Proceeding of the National Academy of Sciences USA, Vol. 92, Sept 1995, pp 9151-9155.	
		SCOTTI, "Soy-derived Protease Inhibitors Treat Cancer and Inflammation", Windhover	
		Information Inc. (1998).	
		SEIBERG ET AL, "Trypsin-Induced Follicular Papilla Apoptosis Results in Delayed Hair Growth	
		and Pigmentation", Developmental Dynamics, Vol. 208, pp 553-564 (1997).	
		SESSA ET AL, "Toasted Soybean Flour Components with Trypsin Inhibitor Activity", JAOCS,	
		Vol. 63, No. 6, pp 784-788 (June 1986)	
		SETCHELL, "High-Performance Liquid Chromatographic Analysis of Phytoestrogens in Soy	
		Protein Preparations with Ultraviolet Electrochemical and Thermospray Mass Spectrometric Detection", <i>Journal of Chromotography</i> , Vol. 386 (1987) pp 315-323, CHROMSYMP. 956.	
		SHARPELL ET AL, "Preservation of Cosmetics", Chapter 51, pp 887-900, Disinfection,	
		Sterilization and Preservation, 4th Edition, Seymour S. Block, Ph. D., Lea & Febiger (1991)	
		publicly available prior to February 28, 2001.	
		SLIGH JR. ET AL, "Inflammatory and Immune Responses are Imparied in Mice Deficient in Intercellular Adhesion Molecule 1", <i>Proc. Natl. Acad., Sci. USA,</i> Vol. 90, 1993, pp 8529-8533.	
		SONG ET AL, "PS04.01.44 Crystal Structure of the Complex of Porcine Pancreatic Trypsin with	
		Kunitz-Type Soybean Trypsin Inhibitor", Crystallography of Biological Macromolecules, p. C-	
	1	106, XVII Congress and General Assembly of the International Union of Crystallog, (1996) (
		www.bmsc.wahingts/abstracts/S0081.html)	
		SONG ET AL, "Kunitz-Type Soybean Trypsin Inhibitor Revisited: Refined Structure of its	
		Complex with Porcine Trypsin Reveals an Insight into the Interaction Between a Homologous	
		Inhibitor from Erythrina Caffra and Tissue-type Plasminogen Activator", J. Mol. Biol., Vol. 275,	
		pp 347-363 (1998).	
		STEENVOORDEN ET AL, "Protection Against UV-Induced Reactive Intermediate in Human	
	i .	Cells and Mouse Skin by Glutathione Precursos: A Comparison of N-Acetylcysteine and	
	ļ	Glutathione Ethylester", <i>Photochemistry and Photobiology</i> , Vol. 67, No. 6, pp 651-656 (1998).	
		STEENVOORDEN ET AL, "The Use of Endogenous Antioxidants to Improve Photoprotection",	
	<u> </u>	Journal of Photochemistry and Photobiology B: Biology, Vol. 41 (1997) pp 1-10.	ļ
		STENN ET AL, "Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration," Skin	
	<u></u> .	Pharmacol., Vol. 6, pp 125-134 (1993).	

E	xaminer	Date
Si	ignature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office. Washington, DC 20231.

Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 22 of 22

T 2	40/000 440
Application Number	10/689,149
Filing Date	10-20-2003
First Named Inventor	Miri Seiberg et al.
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	J&J1886CIP1

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TAN-WILSON, "Relevance of Multiple Soybean Trypsin Inhibitor Forms to Nutritional Quality",	
		Nutritional and Toxicological Significance of Enzyme Inhibitors in Foods, Edited by Mendel Friedman, Chapter 22, pp 391-411 (1985), Department of Biological Sciences, State University	
		of New York at Binghamton.	
		TASHIRO ET AL., "The Complete Amino Acid Sequence of Rice Bran Trypsin Inhibitor", J.	
		Biochem, Vol. 102, No. 2, pp 297-306 (1987).	
	i	TERADA ET AL, "Amino Acid Sequences of Double-headed Proteinase Inhibitors from the	
		Seeds of Canavalia Lineata", Biosci. Biotech. Biochem., Vol. 58, No. 2, pp 376-379 (1994).	1
		THORNTON ET AL, "Effect of Androgens on the Growth of Cultured Human Dermal Papilla Cells Derived from Beard and Scalp Hair Follicles", <i>The Journal of Investigative Dermatology</i> , Vol. 97, No. 2, pp 345-348 (August 1991).	
		TRAVIS ET AL, "The Role Of Proteolytic Enzymes In The Development Of Pumonary	
		Emphysema And Periodontal Disease", American Journal of Respiratory and Critical Care Medicine, Vol. 150,1994, pp S143-S146.	
		TRONNIER ET AL., "Adhesion Molecule Expression In Normal Skin and Melanocytic Lesions",	
		Journal of Cutaneous Pathology, Vol. 24, 1997, pp 278-285.	
		TYRRELL ET AL., "Correlation Between Endogenous Glutathione Content and Sensitivity of	
		Cultured Human Skin Cells to Radiation at Defined Wavelengths in the Solar Ultraviolet Range", <i>Photochemistry and Photobiology</i> , Vol. 47, No. 3, pp 405-412 (1988).	
		VAN DE STOLPE ET AL, "Intercellular Adhesion Molecule-1", <i>J. Mol. Med.</i> , Vol. 74, 1996, pp 13-33.	
		VAN DEN BROEKE ET AL, "Topically Applied N-acetylcysteine as a Protector Against UVB-Induced Systemic Immunosuppression", <i>Journal of Photochemistry and Photobiology, B: Biology</i> , Vol. 27, pp 61-65 (1995).	
		WANG ET AL, "Effects of Soybean Trypsin Inhibitor on Digestive Physiology and Growth and Development of Helicoverpa Armigera Larvae", <i>Acta Entomologica Sinica</i> , Vol. 38, No. 3 (August 1995) pp 272-274.	Yes
		WEBSTER, "Inflammation In Acne Vulgaris", Journal of the American Academy of Dermatology, Vol. 33, No. 2, Part 1, 1995, pp 247-253.	
		WILEY ET AL, "Cardiovascular and Renal - Small-molecule direct thrombin inhibitors", Exp. Opin. Ther. Patents, Vol. 7, No. 11, 1997, pp 1265-1282 (Ashley Publications Ltd. ISSN 1354-3776).	
• •••		XIANG ET AL, "A Study of Nexin 1 of Skin and Hair Follicle during Postnatal Development Period of Rat", Zhongguo Yi Xue Ke Xue Yaun Xue Bao, Vol. 20, No. 2, pp 127-132 (April 1998) ABSTRACT	
		YU ET AL, "Message of Nexin 1, a Serine Protease Inhibitor, is Accumulated in the Follicular Papilla During Anagen of the Hair Cycle", Journal of Cell Science, Vol. 108, Pt 12 (December 1995) pp 3867-3874 ABSTRACT	

Examiner	Date	
Signature	Consid	dered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SUBMISSION UNDER MPEP 609 D

Application Number 10/689,149
Filing Date 10-20-2003
First Named Inventor Miri Seiberg
Group Art Unit 1616
Examiner Name
Attorney Docket Number J&J1886CIP1

Page 1 of 1

11	S	P	ATENT	DOCU	IMENTS

			U.S. Patent Document		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Filing Date	Atty Docket No.
		Halas et al.	10/611,100	07-01-2003	J&J5041
		Seiberg et al.	09/110,409	07-06-1998	JBP0430
		Seiberg et al.	10/659,598	09-10-2003	JBP0430CIP
		Seiberg et al.	09/361,429 / 2002/0065300A1	07-27-1999	JBP0465
		Seiberg et al.	09/206,249	12-07-1998	JBP0438
		Seiberg et al.	10/092,810 / 2002/0197244A1	03-07-2002	JBP0586DIV
		Liu et al.	09/677,511	09-29-2000	JBP0523CIP
		Seiberg et al.	09/621,565	07-20-2000	JBP0510
		Seiberg et al.	10/434,309	05-08-2003	JBP0510DIV
		Seiberg et al.	10/253,736 / 2003/0064048A1	09-23-2002	JBP0510CNT
	<u> </u>	Liu et al.	10/370,680 / 2003/0224075A1	02-20-2003	JBP0585
		Miller et al.	6,555,143 / 2002/0160063A1	02-28-2001	J&J1998
		Liu et al.	09/796,054 / 2002/0160062A1	02-28-2001	J&J2001
		Saliou et al.	09/795,762 / 2002/0160061A1	02-28-2001	J&J2002
		Saliou et al.	10/082,905 / 2002/0192313A1	02-25-2002	J&J2091CIP

FOREIGN PATENT DOCUMENTS

		Name of Patentee or	Foreign Patent Document Pages, Columns, Line where relevant passag or relevant figures	
Examiner Initials	Cite No. ¹	Applicant of Cited Document	Office ³ Number ⁴ KindCode ⁵ appear	
			_	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner 's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

Examiner	Date
Signature	Considered